No press releases found.
Market Chameleon (Thu, 20-Nov 6:51 AM ET)
The SPDR S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index (the Index ). The S&P Biotechnology Select Industry represents the biotechnology segment of the S&P Total Market Index ( S&P TMI ). The S&P TMI is designed to track the broad U.S. equity market. The biotechnology segment of the S&P TMI comprises the Biotechnology sub-industry. The Index is modified equal weighted.
State Street SPDR S&P Biotech ETF trades on the ARCA stock market under the symbol XBI.
As of April 29, 2026, XBI stock price declined to $128.90 with 8,627,923 million shares trading.
XBI has a beta of 0.88, meaning it tends to be less sensitive to market movements. XBI has a correlation of 0.28 to the broad based SPY ETF.
XBI has a market cap of $8.28 billion. This is considered a Mid Cap stock.
In the last 3 years, XBI traded as high as $139.19 and as low as $63.80.
XBI has outperformed the market in the last year with a return of +59.0%, while the SPY ETF gained +30.5%. However, in the most recent history, XBI shares have underperformed the stock market with its stock returning +2.4% in the last 3 month period and -5.0% for the last 2 week period, while SPY has returned +2.6% and +2.5%, respectively.
XBI support price is $128.77 and resistance is $133.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XBI shares will trade within this expected range on the day.
